Rigel Pharmaceuticals | RIGL - Assets


Rigel Pharmaceuticals reported $242.53M in Assets for its fiscal quarter ending in September of 2025.





Assets Change Date
Agenus USD 172.69M 13.76M Jun/2026
Amgen USD 96.05B 409M Sep/2026
Anika Therapeutics USD 183.47M 4.09M Jun/2026
Arrowhead Research USD 2.11B 156.25M Jun/2026
AstraZeneca USD 119.92B 4.09B Sep/2026
BioMarin Pharmaceutical USD 11.57B 154.21M Sep/2026
Bristol-Myers Squibb USD 88.77B 1.14B Sep/2026
Celldex Therapeutics USD 721.53M 60.82M Sep/2026
Daiichi Sankyo JPY 4.26T 144.08B Sep/2026
Eli Lilly USD 148.07B 5.79B Sep/2026
Halozyme Therapeutics USD 3.47B 895.94M Sep/2026
Heron Therapeutics USD 252.26M 6.05M Jun/2026
Intrexon USD 73.16M 77.88M Jun/2024
Ionis Pharmaceuticals USD 2.99B 455.5M Jun/2026
Karyopharm Therapeutics USD 131.42M 23M Mar/2026
Ligand Pharmaceuticals USD 2.24B 51.59M Sep/2026
MacroGenics USD 345.41M 127.54M Jun/2026
Neurocrine Biosciences USD 5.63B 268.3M Sep/2026
Pfizer USD 204.54B 3.41B Sep/2026
Regeneron Pharmaceuticals USD 44.41B 2.67B Sep/2026
Rigel Pharmaceuticals USD 242.53M 35.8M Sep/2025
Sangamo BioSciences USD 97.56M 11.39M Jun/2025
Ultragenyx Pharmaceutical USD 1.19B 77M Sep/2026
Veracyte USD 1.57B 86.89M Sep/2026